JAK Inhibitor Ruxolitinib CRUX Safety and Feasibility Trial Brain 2 Mins Read2 Dr. David Peereboom from Cleveland Clinic conducted a phase one clinical trial called CRUX to investigate the efficacy and safety…
Ruxolitinib Safety and Feasibility in NHGGs: Final Toxicity Report Brain 2 Mins Read0 The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in…
